Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 154

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 1B
Chunk 154
---
 )
     
    $
    112,741

    Issuance of common stock upon vesting of restricted stock units

    41,713

    —

    —

    —

    —

    —

    Issuance of common stock under employee stock purchase plan

    183,378

    —

    108

    —

    —

    108

    Stock-based compensation

    —

    —

    7,407

    —

    —

    7,407

    Unrealized gain on available-for-sale investments

    —

    —

    —

    60

    —

    60

    Net loss

    —

    —

    —

    —

    (63,118
    )

    (63,118
    )

    Balance at December 31, 2024

    38,339,697

    $
    —

    $
    484,504

    $
    97

    $
    (427,403
    )
     
    $
    57,198

See accompanying notes to the consolidated financial statements. 

91

BOLT BIOTHERAPEUTICS, INC. 

CONSOLIDATED STATEMENTS OF CASH FLOWS 

(in thousands) 

    Years Ended December 31,

    2024

    2023

    CASH FLOWS FROM OPERATING ACTIVITIES:

    Net loss
     
    $
    (63,118
    )
     
    $
    (69,197
    )

    Adjustments to reconcile net loss to net cash used in operating activities:

    Depreciation and amortization

    1,781

    1,854

    Stock-based compensation expense

    7,407

    9,223

    Accretion of discount on marketable securities

    (2,615
    )

    (4,493
    )

    Gain on sale of fixed assets

    (70
    )

    —

    Asset impairment

    1,469

    —

    Non-cash lease expense

    2,297

    2,952

    Changes in operating assets and liabilities:

    Prepaid expenses and other assets

    2,571

    (454
    )

    Accounts payable and accrued expenses

    (4,883
    )

    (3,413
    )

    Operating lease liabilities, net

    (1,412
    )

    (2,392
    )

    Deferred revenue